Allogene Therapeutics, Inc. (ALLO) stock
Close on Nov 11, 2026Market cap $310.98MP/E –Yield 0.00%
Allogene Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$108.81M. At the latest close the market valued the company at $310.98M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $310.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- 0.00%
- Free cash flow yield
- -34.99%
Fundamentals
- Revenue
- $0
- Net income
- -$174.46M
- EPS, diluted
- -$0.63
- Free cash flow
- -$108.81M
- Book value per share
- $1.13
- Diluted shares
- 346M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $0.93
- Open
- $0.95
- Day's range
- $0.88 – $0.96
- Volume
- 15,369,380
- Average volume (20 days)
- 10,850,943
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.62
- 52-week range
- $0.88 – $4.46
- RSI (14 days)
- 24.6
- Volatility (1 year)
- 83.4%
- Relative volume
- 2.21×
- WACC
- 13.0%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALLO | S&P 500 | Difference | ALLO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -38.3% | -2.4% | −35.9 pts | ||
| 3 months | -57.5% | -1.2% | −56.4 pts | ||
| Year to date | -34.3% | +12.3% | −46.6 pts | ||
| 1 year | -27.4% | +12.4% | −39.9 pts | ||
| 3 years | -64.0% | +78.8% | −142.8 pts | -28.9% | +21.4% |
| 5 years | -95.3% | +75.2% | −170.5 pts | -45.8% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Allogene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
About Allogene Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biotechnology firm that develops genetically engineered allogeneic T-cell therapies for cancers and autoimmune diseases. Rather than using a patient's own cells, the company engineers donor cells to create standard treatments for broad patient access. Its core product candidates include cemacabtagene ansegedleucel for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune conditions such as systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. The company develops these therapies for individuals diagnosed with blood cancers, solid tumors, and autoimmune disorders.
Company profile, executives and historyAllogene Therapeutics stock: common questions
What is Allogene Therapeutics's stock price?
ALLO closed at $0.90 on Nov 11, 2026, down 3.41% on the day. Over the past 52 weeks it traded between $0.88 and $4.46.
What is Allogene Therapeutics's market cap?
Allogene Therapeutics was worth $310.98M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ALLO's P/E ratio?
Allogene Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.63), so it has no meaningful P/E ratio.
How much revenue does Allogene Therapeutics make?
Allogene Therapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Allogene Therapeutics pay a dividend?
No. Allogene Therapeutics has not paid a cash dividend over the last twelve months.
When does Allogene Therapeutics report earnings next?
Allogene Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ALLO stock performed over the past year?
Including dividends, ALLO returned -27.4% over the past year, against +12.4% for the S&P 500.
How many ALLO shares are sold short?
51M shares were sold short at the latest FINRA report, 17.47% of the float, or 6.2 days of average trading volume.
Who are Allogene Therapeutics's competitors?
Companies most similar to Allogene Therapeutics by business, industry and size include SNTI, LYEL, INMB, ARTV, AIM.
See a number that looks wrong?